Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.

Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK.

Endocr Pract. 2013 Jan-Feb;19(1):19-28. doi: 10.4158/EP12100.OR.

PMID:
23186950
2.
3.

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Mikhail N.

Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845 . Review.

PMID:
18491986
4.

Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

Zerilli T, Pyon EY.

Clin Ther. 2007 Dec;29(12):2614-34. doi: 10.1016/j.clinthera.2007.12.034. Review.

PMID:
18201579
5.

Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.

Gallwitz B.

Drugs Today (Barc). 2007 Jan;43(1):13-25. Review.

PMID:
17315049
6.

Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).

Gallwitz B.

Drugs Today (Barc). 2007 Nov;43(11):801-14. doi: 10.1358/dot.2007.43.11.1157620. Review.

PMID:
18174966
7.

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.

Scheen AJ.

Postgrad Med. 2013 May;125(3):7-20. doi: 10.3810/pgm.2013.05.2659. Review.

PMID:
23748503
8.

Sitagliptin: a novel drug for the treatment of type 2 diabetes.

Choy M, Lam S.

Cardiol Rev. 2007 Sep-Oct;15(5):264-71. Review.

PMID:
17700385
9.

Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.

Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP.

Curr Med Res Opin. 2008 Feb;24(2):489-96. doi: 10.1185/030079908X261069 . Review.

PMID:
18182122
10.

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.

Gallwitz B.

Vasc Health Risk Manag. 2007;3(2):203-10. Review.

11.

[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].

Kleefstra N, van Hateren KJ, Houweling ST, Verhoeven S, Kooy A, Goudswaard AN, Bilo HJ.

Ned Tijdschr Geneeskd. 2010;154:A886. Review. Dutch.

PMID:
20298625
12.

New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.

Gagliardino JJ, Santoro S, Arellano S, Di Girolamo G.

Expert Opin Pharmacother. 2008 Jun;9(9):1495-507. doi: 10.1517/14656566.9.9.1495 . Review.

PMID:
18518780
13.

[New drugs; exenatide and sitagliptin].

van Bronswijk H, Dubois EA, Pijl H, Cohen AF.

Ned Tijdschr Geneeskd. 2008 Apr 12;152(15):876-9. Review. Dutch.

PMID:
18512528
14.

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.

Ahrén B.

Vasc Health Risk Manag. 2008;4(2):383-94. Review.

15.

New combination treatments in the management of diabetes: focus on sitagliptin-metformin.

Green J, Feinglos M.

Vasc Health Risk Manag. 2008;4(4):743-51. Review.

16.

Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.

Davidson JA, Parente EB, Gross JL.

Arq Bras Endocrinol Metabol. 2008 Aug;52(6):1039-49. Review.

17.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

18.

Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.

Plosker GL.

Drugs. 2014 Feb;74(2):223-42. doi: 10.1007/s40265-013-0169-1. Review.

PMID:
24407560
19.

DPP4 inhibitors: a new approach in diabetes treatment.

Doupis J, Veves A.

Adv Ther. 2008 Jul;25(7):627-43. doi: 10.1007/s12325-008-0076-1. Review.

PMID:
18641927
20.

[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].

Abel T, Fehér J.

Orv Hetil. 2010 Jun 20;151(25):1012-6. doi: 10.1556/OH.2010.28910. Review. Hungarian.

PMID:
20519186
Items per page

Supplemental Content

Write to the Help Desk